NewAmsterdam Pharma said regulatory decisions on obicetrapib in Europe, the UK and Switzerland remain expected in 2H26. PREVAIL interim analysis is planned for 4Q2026, with a result expected in 1Q2027.
LIB Therapeutics launched Lerochol in the United States after FDA approval for lowering LDL-C in adults with hypercholesterolemia, including HeFH. The once-monthly PCSK9 inhibitor is available with a $199-per-month cash-pay option.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07685054 |
To Evaluate the Renal Protective Effects and Safety of 'Fimasartan and Atorvastatin' or 'Fimasartan, Atorvastatin and Ezetimibe'. |
NOT_YET_RECRUITING | |
| NCT06386419 |
A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia |
COMPLETED | PHASE4 |
| NCT06165250 |
A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C |
COMPLETED | PHASE3 |
